mitotempo and Non-alcoholic-Fatty-Liver-Disease

mitotempo has been researched along with Non-alcoholic-Fatty-Liver-Disease* in 1 studies

Other Studies

1 other study(ies) available for mitotempo and Non-alcoholic-Fatty-Liver-Disease

ArticleYear
Protective Effects of MitoTEMPO on Nonalcoholic Fatty Liver Disease via Regulating Myeloid-Derived Suppressor Cells and Inflammation in Mice.
    BioMed research international, 2020, Volume: 2020

    MitoTEMPO, a mitochondrial antioxidant, has protective effects on liver-related diseases. However, the role of MitoTEMPO on nonalcoholic fatty liver disease (NAFLD) and its possible mechanisms are largely unknown. Here, we investigated the effects of MitoTEMPO on NAFLD using high fat diet- (HFD-) induced obese mice as animal models. MitoTEMPO was intraperitoneally injected into HFD mice. Liver morphological changes were observed by H&E and Oil Red O staining, and the frequency of MDSCs in peripheral blood was analyzed by flow cytometry. Moreover, real-time quantitative PCR, western blot, and immunohistochemistry were conducted to detect the mRNA and protein expressions in the liver tissues. The results showed that the hepatic steatosis in liver tissues of HFD mice injected with MitoTEMPO was significantly ameliorated. Additionally, MitoTEMPO reduced the frequency of CD11b

    Topics: Animals; Gene Expression Regulation; Inflammation; Liver; Male; Mice; Myeloid-Derived Suppressor Cells; Non-alcoholic Fatty Liver Disease; Organophosphorus Compounds; Piperidines

2020